Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.64 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.64 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.64 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.64 |
| ▸ | CDK8 | P49336 | 6/20 | 0.61 |
| ▸ | AXL | P30530 | 2/20 | 0.61 |
| ▸ | RIPK1 | Q13546 | 4/20 | 0.58 |
| ▸ | BRD4 | O60885 | 1/20 | 0.55 |
| ▸ | PDGFRB | P09619 | 5/20 | 0.54 |
| ▸ | PDGFRA | P16234 | 5/20 | 0.54 |
| ▸ | PLK4 | O00444 | 2/20 | 0.51 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.51 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.51 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.51 |
| ▸ | INSR | P06213 | 2/20 | 0.51 |
| ▸ | CDK1 | P06493 | 2/20 | 0.51 |
| ▸ | ROS1 | P08922 | 2/20 | 0.51 |
| ▸ | FER | P16591 | 2/20 | 0.51 |
| ▸ | CDK2 | P24941 | 2/20 | 0.51 |
| ▸ | MARK3 | P27448 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4831501 | 0.84 | CDK8 (0.81) | PIK3CDPIK3CAPIK3CBPIK3CGCDK8 | |
| SCHEMBL14365341 | 0.81 | PIK3CD (0.47) | PIK3CDPIK3CAPIK3CBPIK3CGCDK8 | |
| SCHEMBL29930506 | 0.79 | PDGFRB (0.55) | PIK3CACDK8AXLPDGFRBPDGFRA | |
| SCHEMBL416750 | 0.78 | PIK3CA (1.00) | PIK3CDPIK3CAPIK3CBPIK3CGCDK8 | |
| SCHEMBL8501291 | 0.77 | PDGFRB (0.51) | PIK3CGCDK8AXLPDGFRBPDGFRA | |
| SCHEMBL410704 | 0.76 | CDK8 (1.00) | PIK3CDPIK3CAPIK3CBPIK3CGCDK8 | |
| SCHEMBL3767742 | 0.76 | MAP3K11 (0.78) | CDK8ROCK2INSRCDK1CDK2 | |
| SCHEMBL415099 | 0.75 | PIK3CA (0.70) | PIK3CDPIK3CAPIK3CBPIK3CGCDK8 | |
| SCHEMBL22978455 | 0.73 | RIPK1 (1.00) | PIK3CDPIK3CAPIK3CBPIK3CGCDK8 | |
| SCHEMBL13854148 | 0.73 | CDK8 (0.65) | PIK3CDPIK3CAPIK3CBPIK3CGCDK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180111929-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2018-04-26 | — | — | US | disclosed |
| US-20180111929-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2018-04-26 | — | — | US | disclosed |
| US-20160176865-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2016-06-23 | — | — | US | disclosed |
| US-20160176865-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2016-06-23 | — | — | US | disclosed |
| US-20150290205-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2015-10-15 | — | — | US | disclosed |
| US-20150290205-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2015-10-15 | — | — | US | disclosed |
| US-20130261117-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2013-10-03 | — | — | US | disclosed |
| US-20130261117-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2013-10-03 | — | — | US | disclosed |
| US-8470818-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-8470818-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2013-06-25 | — | — | US | disclosed |
| EP-1893612-A1 | PYRROLO [2, 3-B]PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | PLEXXIKON, INC. (US) | 2008-03-05 | — | — | EP | disclosed |
| US-7291630-B2 | Azaindoles as inhibitors of c-Jun N-terminal kinases | EISAI CO., LTD. (JP) | 2007-11-06 | — | — | US | disclosed |
| US-7291630-B2 | Azaindoles as inhibitors of c-Jun N-terminal kinases | EISAI CO., LTD. (JP) | 2007-11-06 | — | — | US | disclosed |
| US-20070066641-A1 | Compounds and methods for development of RET modulators | PLEXXIKON, INC. | 2007-03-22 | — | — | US | disclosed |
| CN-1925855-A | Compounds and methods for development of Ret modulators | PLEXXIKON INC (US) | 2007-03-07 | — | — | CN | disclosed |
| US-20070049615-A1 | Compounds and methods for development of Ret modulators | PLEXXIKON, INC. | 2007-03-01 | — | — | US | disclosed |
| WO-2007002433-A1 | PYRROLO [2, 3-B] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | PLEXXIKON, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| WO-2007002433-A1 | PYRROLO [2, 3-B] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | PLEXXIKON, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| EP-1696920-A2 | COMPOUNDS AND METHODS FOR DEVELOPMENT OF RET MODULATORS | PLEXXIKON, INC. (US) | 2006-09-06 | — | — | EP | disclosed |
| WO-2005062795-A2 | COMPOUNDS AND METHODS FOR DEVELOPMENT OF RET MODULATORS | PLEXXIKON, INC. (US) | 2005-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130261117-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | PIK3CD 139/4885PIK3CA 79/4885PIK3CB 136/4885 |
| US-20180111929-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | PIK3CD 139/4885PIK3CA 79/4885PIK3CB 136/4885 |
| US-20150290205-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | PIK3CD 139/4885PIK3CA 79/4885PIK3CB 136/4885 |
| US-20070066641-A1 | Compounds and methods for development of RET modulators | RET, FGFR1, FGFR3 | PIK3CD 2696/4885PIK3CA 2137/4885PIK3CB 2522/4885 |
| US-20160176865-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | PIK3CD 139/4885PIK3CA 79/4885PIK3CB 136/4885 |
| US-20070049615-A1 | Compounds and methods for development of Ret modulators | RET, GFRA1, GFRA3 | PIK3CD 4141/4885PIK3CA 4402/4885PIK3CB 4063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.